• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    89.59 +3.58 (+4.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    News headline image
    Arrowhead Pharmaceuticals Q3 Earnings Call Highlights ↗
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗
    Via Chartmill
    Gapping stocks in Wednesday's session ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer... 
    Via MarketBeat
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in... 
    Via MarketBeat
    News headline image
    Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a... 
    Via MarketBeat
    News headline image
    Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
    Arrowhead (ARWR) Q2 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
    Arrowhead Pharmaceuticals (ARWR) combines strong revenue growth and profitability with a bullish technical chart pattern, signaling a potential breakout for this RNAi therapy developer. 
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
    Via MarketMinute
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.